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ABSTRACT
This review examines the available literature on
the effect of glucagon-like peptide-1 receptor
agonists (GLP-1RAs) on renal outcomes in type
2 diabetes mellitus. Diabetes is an important
cause of end-stage renal disease requiring renal
replacement therapy, and diabetic kidney dis-
ease is an independent risk factor for cardio-
vascular disease (CVD). GLP-1RAs are proven to
be safe in terms of CVD, and some of them have
been shown to have a beneficial effect on car-
diovascular outcomes. The effect of GLP-1RAs
on hard renal endpoints has yet to be estab-
lished; to date, there have been no published
GLP-1RA clinical trials with primary renal end-
points. In this review, we discuss the evidence
for a renal protective role of GLP-1RAs, high-
lighting the secondary renal outcomes from
recent cardiovascular outcome trials of this class
of glucose-lowering therapies.
Keywords: Chronic kidney disease; Diabetes-
related nephropathy; Diabetic nephropathy;
Dipeptidyl peptidase-4 (DPP-4) inhibitors;
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Key Summary Points
Glucagon-like peptide-1 receptor agonists
(GLP-1RAs) are safe and effective in
patients with renal function decline.
GLP-1RAs reduce the emergence and
progression of proteinuria.
The impact of GLP-1RA on estimated
glomerular filtration rate (eGFR) decline is
marginal.
No benefits have been observed on hard
renal endpoints.
Further studies with a unified composite
renal endpoint and longer duration are
needed.
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INTRODUCTION
Diabetes is the leading cause of chronic kidney
disease (CKD) and 40% of patients with type 2
diabetes (T2DM) are affected by diabetic kidney
disease (DKD) [1]. In addition, DKD is the single
most common cause of end-stage renal disease
(ESRD) requiring renal replacement therapy
(RRT) [2]. Patients with T2DM and DKD are at
increased risk of developing cardiovascular dis-
ease (CVD), and DKD itself is an independent
risk factor for hypertension and premature
death. Recent years have seen changes in dia-
betes management, moving away from a glu-
cocentric approach to multifactorial risk factor
modification with a consequent reduction in
incidence of T2DM-related CV morbidity and
mortality by[ 50%. However, the incidence of
T2DM-related ESRD decreased by only 29% [3].
SEARCH STRATEGY
Publications were identified through searches of
Medline, PubMed, Web of Science and Google
Scholar. Search terms included ‘diabetes kidney
disease’, ‘diabetic nephropathy’, ‘chronic kid-
ney disease’, ‘diabetes cardiovascular outcome
trials’, ‘microvascular’, ‘glucagon-like peptide’,
‘cardiovascular’, ‘macrovascular’, ‘renal out-
come’ and ‘type 2 diabetes’. Articles were
excluded if they were case reports, editorials or
small studies that the authors felt had
methodological limitations. All studies pub-
lished in English were included and reviewed by
the authors. This article is based on previously
conducted studies and does not contain any
studies with human participants or animals
performed by any of the authors.
DIABETIC KIDNEY DISEASE:
DIAGNOSIS AND PROGNOSIS
DKD, also known as diabetic nephropathy, is
clinically defined by a persistently elevated uri-
nary albumin: creatinine ratio
(UACR) C 30 mg/g (or C 3.4 mg/mol) and/or a
sustained reduction in estimated glomerular
filtration rate (eGFR)\ 60 ml/min/1.73 m2 [4].
Classical pathological changes of DKD are divi-
ded into five stages, which occur over a period
of 5–15 years. In brief, they are: stage 1, hyper-
function and hypertrophy of the kidneys; stage
2, histological morphological changes with
increased glomerular filtration rate (GFR) and
urinary albumin excretion (UAE) with exercise;
stage 3, incipient diabetic nephropathy with
mildly abnormal UAE rates termed microalbu-
minuria; stage 4, overt diabetic nephropathy
with UAE[ 0.5 g/24 h, hypertension and
declining eGFR; stage 5, ESRD [5]. Clinical
manifestations of DKD differ between people
with type 1 diabetes (T1DM) and those with
T2DM. While patients with T1DM typically
present with the stages of nephropathy descri-
bed above, heterogenicity exists in people with
T2DM. Thus, patients may present with
microalbuminuria and elevated blood pressure,
without their being progression through the
stages. Patients with T2DM may also have sig-
nificant co-morbidities such as obesity, hyper-
tension or CVD, which have pre-dated their
diagnosis of diabetes.
Microalbuminuria [an albumin excretion
rate (AER) of 20–200 mcg/min] is the earliest
clinical manifestation of DKD in T1DM and
thought to be predictive of DKD progression in
patients with T2DM. The progression rate from
normoalbuminuria to microalbuminuria, and
from microalbuminuria to macroalbuminuria,
is approximately 2%/year. In the UKPDS study,
15 years after diagnosis, 40% of patients had
macroalbuminuria and 30% had an
eGFR\ 60 ml/min/1.73 m2 or a doubling of
serum creatinine [6]. The progression of
microalbuminuria to macroalbuminuria does
not occur in all patients and may regress in
some. The progression of albuminuria is influ-
enced by blood pressure, lipids and glycaemic
control [7].
GLUCAGON-LIKE PEPTIDE-1
RECEPTOR AGONISTS
Glucagon-like peptide-1 receptor agonists (GLP-
1RA) decrease blood glucose levels by stimulat-
ing glucose-dependent insulin secretion,
inhibiting glucagon secretion, reducing gastric
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emptying, reducing appetite and promoting
satiety [8]. Currently, there are six GLP-1RA
injectables [exenatide (bid daily), exenatide
(once weekly), lixisenatide (once daily),
liraglutide (once daily), dulaglutide (once
weekly) and semaglutide (once weekly)]
approved in Europe and the USA and one GLP-
1RA oral formulation (semaglutide) in the USA.
A further one (albiglutide), has never been
launched in the UK and was withdrawn from
global use in 2018. Three GLP-1RAs are mainly
eliminated by the kidneys and the remaining
ones by peptidases and the kidneys. Therefore,
all have license limitations based on the stages
of CKD (Table 1).
Preclinical studies demonstrated GLP-1
receptor expression in the proximal tubular
cells, glomeruli and vascular smooth muscle
cells of kidney [9, 10]. However, the mecha-
nisms for any potential renoprotective effect of
GLP-1RA have yet to be established. Proposed
mechanisms include renal tubular effects, a
renal haemodynamic effect and reduction in
renal oxidative stress. The renal tubular effects
of GLP-1 are thought to be due to its natriuretic
and diuretic properties. In both animal [11] and
human studies involving healthy subjects, as
well as subjects with T2DM, GLP-1 infusion was
shown to promote natriuresis and diuresis by
inhibition of the sodium-hydrogen exchanger 3
(NHE3) localized at the brush border of the
renal proximal tubule. Infusion of lixisenatide
[12], exenatide [13] and liraglutide [14] in peo-
ple with T2DM has been shown to reduce uri-
nary sodium reabsorption and increase
proximal urinary sodium excretion. Evidence
concerning the glomerular haemodynamic
effects of GLP-1 are conflicting. Zhou et al.
demonstrated that infusion of the GLP-1 RA
liraglutide improved sodium and water han-
dling and increased GFR in rats [15]. However,
human studies with lixisenatide, exenatide and
liraglutide showed no effect on renal haemo-
dynamics (GFR or renal blood flow) [12, 13].
GLP-1 is also thought to have antioxidant
properties. GLP-1RA knockout mice showed
higher levels of albuminuria and more
advanced mesangial expansion. Liraglutide
administration in these mice delayed progres-
sion of DKD by a reduction in mesangial
expansion and reduced levels of glomerular
superoxide along with increased levels of renal
nitric oxide [16]. Some studies suggested that
the renoprotective effect of GLP-1 is mediated
by metabolites of innate GLP-1 such as GLP-1
(9–37) and GLP-1 (28–37). In the animal studies,
GLP-1 metabolites did not have an effect on
glucose metabolism but were associated with
lowered expression of renal tubular injury
markers and less tubulointerstitial damage by
decreasing accumulation of macrophages and T
cells in kidneys [17].
RENAL OUTCOMES IN GLP-1RA
CLINICAL TRIALS
Since the publication of US Food and Drug
Administration (FDA) guidance in 2008, robust
cardiovascular safety data in patients with
T2DM is a prerequisite for approval of glucose-
lowering therapies [18]. All GLP-1RAs (except
Exenatide bid daily) were assessed for cardio-
vascular safety and some have shown
Table 1 Glucagon-like peptide-1 receptor agonists and
their license limitation as per renal function
GLP1 receptor
agonists
Renal license limitation
Exenatide BD (Byetta) eGFR 30-50 ml/min—use with
caution
eGFR\ 30 ml/min—not
recommended
Exenatide QW
(Bydureon)
eGFR\ 50 ml/min—not
recommended
Lixisenatide
(Lyxumia)
eGFR\ 30 ml/min—not
recommended
Liraglutide (Victoza) eGFR\ 15 ml/min—not
recommended
Dulaglutide
(Trulicity)
eGFR\ 15 ml/min—not
recommended
Semaglutide
(Ozempic)
eGFR\ 15 ml/min—not
recommended
eGFR estimated glomerular filtration rate
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Table 2 GLP-RA clinical trials with renal outcome
Trial (n) Drug Patient
characteristics
Follow-
up
(years)
Renal endpoint Exploratory renal outcome
(change from baseline or HR
95% CI)
ELIXA
(n = 6068:
CVOT)
(n = 5633:
Renal)
Lixisenatide T2DM with recent
ACS
2.1 Change in UACR
(%)
Normoalbuminuria
(74%)
- 1.69 (SE 5.10)
Microalbuminuria
(19%)
- 21.10 (SE 10.79)
Macroalbuminuria
(7%)
- 39.18 (SE 14.97)*
LEADER
(n = 9340)
Liraglutide T2DM with
established CVD or
CV risk factor
Established CVD
(72.4%)
CKD stage 3 or
higher (24%)
Both CVD and CKD
(15.8%)
3.8 Time to primary
composite
endpoint
HR 0.78 (0.67–0.92)*
Time to new
macroalbuminuria
HR 0.74 (0.60–0.91)*
Persistent doubling
of Cr
HR 0.89 (0.67–1.19)
Chronic RRT HR 0.87 (0.61–1.24)
Renal death HR 1.59 (0.52–4.87)
LIRA-
RENAL
(n = 279)
T2DM with CKD
stage 3
0.5 Change in eGFR 2% lower reduction
Change in UACR HR0.83 (0.62–1.10)
SUSTAIN-6
(n = 3297)
Semaglutide T2DM with
established CVD or
CV risk factors
Established CVD
(83%)
2.1 New or worsening
nephropathy
HR 0.64 (0.46–0.88)*
Persistent
microalbuminuria
HR 0.54 (0.37–0.77)*
Persistent doubling
of Cr
HR 1.28 (0.64–2.58)
Chronic RRT HR 0.91 (0.40–2.07)
EXSCEL
(n = 14,752)
Exenatide Established CVD
(73%)
3.2 Change in eGFR LSMD ? 0.21 (- 0.27, 0.70)
mL/min 1.73 m2
New onset
macroalbuminuria
2.2% vs 2.5%
Renal composite 1a HR 0.87 (0.73–1.04)
Renal composite 2a HR 0.85 (0.73–0.98)*
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favourable CV outcome, i.e. reduction in major
adverse cardiovascular events (MACE). Most of
these studies incorporated secondary explora-
tory renal endpoints; however, to date, there are
no published GLP-1RA clinical trials that were
designed to assess renal outcomes as a primary
endpoint. In this section, we will discuss pub-
lished secondary renal outcomes of each GLP-
1RA, in the chronological order of their
published cardiovascular outcome trials
(CVOTs) (Table 2).
Lixisenatide
The primary results of the lixisenatide CVOT
(ELIXA) was published in 2015, demonstrating
non-inferiority of lixisenatide compared with
Table 2 continued
Trial (n) Drug Patient
characteristics
Follow-
up
(years)
Renal endpoint Exploratory renal outcome
(change from baseline or HR
95% CI)
Harmony
outcome
(n = 9463)
Albiglutide T2DM with
established CVD
1.5 Microvascular events
including renal
events
HR 0.66 (0.43, 1.01)
REWIND
(n = 9901)
Dulaglutide T2DM with
established CVD or
CV risk factors
Macroalbuminuria
(7.9%)
5.4 Composite renal
outcome
HR 0.85 (0.77–0.93)*
New
macroalbuminuria
HR 0.77 (0.68–0.87)*
Sustained decline in
eGFR[ 30 form
baseline
HR 0.89 (0.78–1.01)
Chronic RRT HR 0.75 (0.39–1.44)
AWARD-7
(n = 577)
Dulaglutide
0.75 mg
vs
Dulaglutide
1.5 mg vs
vs glargine
T2DM with CKD
stage 3–4
1.0 Change in eGFR Dulaglutide 1.5 mg: LSM
34 ml/min
Dulaglutide 0.75 mg: LSM
33.8 ml/min
Insulin glargine: LSM 31.3 ml/
min
Change in UACR Dulaglutide 1.5 mg: LSM
- 22.5%
Dulaglutide 0.75 mg: LSM
- 20.1%
Insulin glargine: LSM - 13.0%
T2DM type 2 diabetes, CVOT cardiovascular outcome trial, UACR urinary albumin creatinine ratio, CVD cardiovascular
disease, CKD chronic kidney disease, Cr serum creatinine, RRT renal replacement therapy, eGFR estimated glomerular
filtration rate, HR hazard ratio, CI confident interval, LSMD least squared mean difference, LSM least squared mean
*Statistically significant
a Renal composite 1: 40% eGFR decline, RRT and renal death; renal composite 2: 40% eGFR decline, RRT, renal death
and new macroalbuminuria
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placebo in 6068 T2DM patients with a recent
acute coronary syndrome [19]. Subsequent renal
exploratory analysis, published in 2018, exam-
ined the percentage change in UACR and eGFR,
according to prespecified albuminuria status at
baseline [normoalbuminuria (UACR\ 30 mg/
g); microalbuminuria (C 30 to B 300 mg/g);
macroalbuminuria ([ 300 mg/g)] and time to
new-onset macroalbuminuria and doubling of
serum creatinine [20]. The UACR data were
available for 5978 (99% of primary ELIXA
cohort); 4441 (74%) had normoalbuminuria,
1148 (19%) had microalbuminuria, and 389
(7%) had macroalbuminuria. After a median
follow-up of 108 weeks, a significant reduction
in UACR [- 39.18%, 95% confidence interval
(CI) - 68.53 to - 9.84; p = 0.007] was observed
in patients with macroalbuminuria on lixisen-
atide compared with those on placebo. The
largest eGFR decline from baseline was also
observed in the macroalbuminuric group, but
no significant differences were observed
between the two treatment groups or any UACR
subgroups. Lixisenatide was associated with a
20% relative risk (RR) reduction in new onset
macroalbuminuria (HR 0.808; 95% CI
0.660–0.991; p = 0.0404), when adjusted for
baseline haemoglobin A1c (HbA1c), on trial
HbA1c and other renal risk factors. There were
no differences in the proportion of patients
with adverse renal events [48 (1.6%) of 3032
patients in the placebo group vs. 48 (1.6%) of
3031 patients in the lixisenatide group] and the
proportion of patients with doubling of serum
creatinine [35 (1%) of 3032 patients in the pla-
cebo group and 41 (1%) of 3031 patients in the
lixisenatide group (HR 1.163, 95% CI
0.741–1.825; p = 0.5127)].
Liraglutide
The LEADER trial assessed the cardiovascular
safety of liraglutide 1.8 mg once daily compared
with a placebo, in addition to the standard
medical care [21]. The trial enrolled 9340
patients with T2DM (72.4% had established
CVD, 24% either CKD stage 3 or higher and
15.8% both CVD and CKD) and the median
follow-up was 3.8 years. The LEADER trial
reported renal outcomes in its secondary
exploratory analysis [22]. The prespecified renal
outcome was a composite of new-onset persis-
tent macroalbuminuria, persistent doubling of
the serum creatinine, ESRD or death due to
renal disease. The trial demonstrated that the
liraglutide group had fewer occurrences of the
composite renal outcome than the placebo
group (268 of 4668 patients vs. 337 of 4672; HR
0.78; 95% CI 0.67–0.92; p = 0.003). That was
primarily due to a reduction in new-onset per-
sistent macroalbuminuria, which occurred in
significantly fewer participants in the liraglutide
group than in the placebo group (161 vs. 215
patients; HR 0.74; 95% CI 0.60–0.91; p = 0.004).
Numerical reduction in persistent doubling of
serum creatinine (87 vs. 97 patients; HR 0.89;
95% CI 0.67–1.19; p = 0.43) and the need for
continuous renal replacement therapy (56 vs.
64 patients; HR 0.87; 95% CI 0.61–1.24;
p = 0.44) were also observed in the liraglutide
group compared with the placebo group. There
were no significant differences in the rates of
renal adverse events between liraglutide and
placebo (15.1 events and 16.5 events per 1000
patient-years), including the rate of acute kid-
ney injury (AKI) (7.1 and 6.2 events per 1000
patient-years, respectively).
Another liraglutide study (LIRA-RENAL—a
26-week, randomised controlled double-blind
trial, n = 279) was designed to examine the
efficacy and safety of liraglutide as an add-on to
existing glucose-lowering therapy in people
with T2DM and moderate renal impairment
(eGFR 30–59 ml/min/1.73 m2 as per MDRD
formula) [23]. No significant changes in renal
function were observed between the two
groups. However, there were a 2% lower relative
difference from baseline eGFR (p = 0.3575) and
a 17% RR reduction in UACR (HR 0.83, 95% CI
0.62–1.10; p = 0.1856) in the liraglutide group
compared with placebo.
Semaglutide
The SUSTAIN-6 trial was designed to assess non-
inferiority of semaglutide compared with a
placebo in terms of cardiovascular safety in
patients with T2DM [24]. It enrolled 3297
patients and the median follow-up was
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2.1 years. As was the case in the LEADER trial, it
included pre-specified renal microvascular out-
comes (defined as persistent macroalbuminuria,
doubling of serum creatinine or eGFR\ 45 and
RRT). New or worsening nephropathy occurred
in 62 patients (3.8%) in the semaglutide group
and 100 (6.1%) in the placebo group (HR 0.64;
95% CI 0.46–0.88; p = 0.005). This benefit was
once again driven by a fall in new cases of per-
sistent macroalbuminuria (2.5% versus 4.9% of
cases) whereas the number of patients who had
a doubling of serum creatinine and/or needed
continuous RRT was small and similar between
groups.
Exenatide
The EXSCEL trial is the largest CVOT of a GLP-
1RA, assessing cardiovascular safety of once-
weekly exenatide compared with placebo on the
background of usual care in 14,752 patients with
T2DM (73.1% had previous CVD) [25]. Renal
outcomes in the EXSCEL trial were changes in
eGFR, occurrence of newmacroalbuminuria and
two renal composites (renal composite 1: 40%
decline in eGFR, RRT, renal death and renal
composite 2: 40% decline in eGFR, RRT, renal
death and new macroalbuminuria) from a pre-
specified analysis plan. Intention-to-treat analy-
ses showed no significant difference in eGFR
levels and development of new macroalbumin-
uria but a 15% lower renal composite 2 adjusted
risk with exenatide (p = 0.027) [26].
Albiglutide
The Harmony Outcomes trial was designed to
assess cardiovascular safety of once-weekly
albiglutide compared with a placebo in patients
with T2DM and CVD [27]. The trial included
9463 patients with a median follow-up of
1.5 years. No differences in the rate of eGFR
decline and renal events were noted between
the two groups.
Dulaglutide
In the AWARD-7 trial, once-weekly dulaglutide
0.75 mg and 1.5 mg was compared with insulin
glargine in 577 patients with T2DM and mod-
erate-to-severe CKD [28]. The secondary out-
comes of this trial included renal endpoints:
change in eGFR and UACR. At 52 weeks, eGFR
decline from baseline was less in both dulaglu-
tide groups (34.0 ml/min/1.73 m2 in dulaglu-
tide 1.5 mg; p = 0.005 vs. insulin glargine and
33.8 ml/min/1.73 m2 in dulaglutide 0.75 mg;
p = 0.009 vs. insulin glargine). There was a sig-
nificant reduction in UACR from baseline in all
three treatment groups but no significant dif-
ferences between treatment groups.
The REWIND study was the cardiovascular
safety trial of once-weekly dulaglutide 1.5 mg
vs. placebo in 9901 patients with T2DM and a
previous cardiovascular event or cardiovascular
risk factors [29]. Trial recruits had a baseline
mean eGFR of 76.9 ml/min/1.73 m2 and 791
(7.9%) had macroalbuminuria. The composite
renal outcome was defined as the first occur-
rence of new macroalbuminuria
(UACR[ 33.9 mg/mol), a sustained reduction
in eGFR of 30% or more from baseline or the
need for RRT [30]. During a median follow-up of
5.4 years, dulaglutide was associated with a 15%
RR reduction in the composite renal outcome
(HR 0.85, 95% CI 0.77–0.93; p = 0.0004). Simi-
lar to the LEADER and SUSTAIN-6 trials, the
renal benefit was driven by the development of
new macroalbuminuria, which occurred in 441
(8.9%) of 4949 patients assigned to dulaglutide
and in 561 (11.3%) of 4952 patients on placebo
(HR 0.77, 95% CI 0.68–0.87, p\ 0.0001). No
significance differences in sustained reduction
of eGFR[30% and RRT were observed between
the two groups. The dulaglutide group had
lower eGFR decline [overall LSM difference 0.42
(95% CI - 0.011 to 0.96); p = 0.12] and lower
UACR [overall LSM difference 0.82 (95% CI
0.78–0.86), p\ 0.001] compared with the pla-
cebo group.
RENAL ADVERSE EVENTS
There have been case reports of AKI [31] and
interstitial nephritis associated with GLP-1RA
administration [32]. Subsequent cardiovascular
outcome studies did not support these findings
[20, 22, 25, 27, 30] and animal studies have
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reported a renoprotective effect against AKI
[33]. One possible explanation is that GLP-1RA-
induced AKI might be related to gastrointestinal
side effects of GLP-1RA such as severe nausea,
vomiting and diarrhoea with subsequent dehy-
dration. The other hypothetical explanation is
GLP-1-induced glomerular haemodynamic
changes. Gutzwiller et al. suggested a tubu-
loglomerular feedback mechanism: reduced
sodium reabsorption leads to more sodium
availability to the macula densa, which in turn
activates tubuloglomerular feedback and affer-
ent arteriolar vasoconstriction with a subse-
quent reduction in eGFR and creatinine
clearance [34]. Of note, patients who developed
GLP-1-induced AKI were taking stable doses of
an angiotensin-converting enzyme inhibitor/
angiotensinogen 2 receptor blocker or diuretics
[35].
CONCLUSIONS
The secondary or exploratory renal outcomes
from GLP-1RA cardiovascular outcome trials
suggest a renal protective effect of GLP-1RA. A
recent meta-analysis of these trials confirms
that GLP-1RAs were associated with a 17% RR
reduction in a broad renal composite outcome
consisting of occurrence of macroalbuminuria,
doubling of serum creatinine or eGFR decline of
C 40%, RRT and renal death (HR 0.83; 95% CI
0.78–0.89; p\0.0001) over a median follow-up
of 3.2 years [36]. The renal benefit of GLP-1RA
was almost entirely driven by reduction in UAE
and not by hard renal endpoints such as decline
in eGFR, ESRD or kidney-related death. All of
the GLP-1RA trials considered above were
designed to assess cardiovascular safety and
renal outcomes were included as secondary
endpoints or exploratory analyses. These stud-
ies, therefore, did not have enough power to
detect hard-renal outcomes. There is no GLP-
1RA trial yet published that assesses renal out-
comes as a primary endpoint. A placebo-con-
trolled trial of semaglutide by injection with
primary renal endpoints (FLOW) [37] is cur-
rently on-going and expected to report in 2024.
The primary endpoint for the study is time to
first occurrence of a composite of persistent
eGFR decline C 50% from baseline, ESRD
(eGFR\15 ml/min, dialysis or transplanta-
tion), death from kidney disease or death from
cardiovascular disease. Further long-term trials
of GLP-1RAs with primary renal endpoints are
needed to firmly establish a clinically relevant
renoprotective effect of GLP-1RA rather than
reduction in the surrogate marker of UAE. It
would also be helpful if such trials could adopt a
unified composite renal endpoint [38] (as has
been the case with the CVOTs) to allow for
meaningful between-trial comparisons and
meta-analysis.
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